DUBLIN--(BUSINESS WIRE)--The "Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
The nuclear medicine market is projected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, growing at a CAGR of 4.7% during the forecast period.
The nuclear medicine market is projected to grow at a CAGR of 4.7%
The key factors propelling the growth of this market are the increasing incidence and prevalence of cancer & cardiovascular diseases and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices have made it difficult for a section of end-users to depend on nuclear medicine. These factors are expected to hamper the growth of the nuclear medicine market during the forecast period. The Technetium-99m segment to hold the largest share of SPECT radiopharmaceuticals market in 2019 Based on type, the SPECT radiopharmaceuticals market is segmented Tc-99m, Tl-201, Ga-67, I-123, and other isotopes. In 2019, the Tc-99m segment is expected to command the largest share of the SPECT radiopharmaceuticals market. The large share of this segment can be attributed to the fact that Tc-99m is the most commonly used diagnostic radioisotope, which is used in around 80-90% of diagnostic scans and around 30 million patient examinations every year.
In 2018, the thyroid indications segment accounted for the largest share of the therapeutics market
On the basis of indication, the therapeutic nuclear medicine applications market is segmented into thyroid indications, bone metastasis, lymphoma, endocrine tumors, and other indications. In 2018, the thyroid indications segment accounted for the largest share of the therapeutics market. On the other hand, the endocrine tumors segment is expected to grow at the highest CAGR during the forecast period. The growth in this segment is majorly driven by the increasing use of therapeutic radiopharmaceuticals in the treatment of endocrine tumors.
The Asia Pacific to witness the highest growth during the forecast period
Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2019-2024. The major factors driving the growth of the Asia Pacific market include research initiatives in Japan, rising installations of PET scanners in India and China, and initiatives by the Australian government.
Key Benefits of Buying the Report:
This report focuses on various levels of analysis - industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the nuclear medicine market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the nuclear medicine market.
Key Topics Covered:
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.3 Market Size Estimation Methodology
2.4 Market Data Validation and Triangulation
2.5 Assumptions for the Study
3 Executive Summary
4 Premium Insights
4.1 Nuclear Medicine: Market Overview
4.2 Geographic Analysis: Nuclear Medicine Market for PET Applications, By Type (2017)
4.3 Nuclear Medicine Market Share, By Type, 2018 vs. 2023
4.4 Geographical Snapshot of the Nuclear Medicine Market
5 Market Overview
5.1.1 Introduction
5.1.2 Market Dynamics
5.1.3 Drivers
5.1.4 Restraints
5.1.5 Opportunities
5.1.6 Challenges
6 Nuclear Medicine/Radiopharmaceuticals Market, By Type
6.1 Introduction
6.2 Diagnostic Nuclear Medicine
6.3 Therapeutic Nuclear Medicine
7 Nuclear Medicine/Radiopharmaceuticals Market, By Application
7.1 Introduction
7.2 Diagnostic Applications
7.3 Therapeutic Applications
8 Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume
8.1 Introduction
8.2 Diagnostic Procedures
8.3 Therapeutic Procedures
9 Nuclear Medicine/Radiopharmaceuticals Market, By Region
9.1 Introduction
9.2 North America
9.3 Europe
9.4 Asia Pacific
9.5 Rest of the World
10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis
10.3 Competitive Scenario
11 Company Profiles
11.1 Cardinal Health
11.2 GE Healthcare (A Fully-Owned Subsidiary of General Electric Company)
11.3 Curium
11.4 Lantheus Medical Imaging
11.5 Bayer
11.6 Bracco Imaging
11.7 Eczacibasi-Monrol Nuclear Products
11.8 Nordion (A Subsidiary of Sterigenics International)
11.9 Advanced Accelerator Applications (Aaa, Acquired By Novartis)
11.10 NTP Radioisotopes Soc, Ltd
11.11 Joint Stock Company Isotope (JSC Isotope)
11.12 Northstar Medical Radioisotopes, LLC
11.13 Eckert & Ziegler
11.14 Jubilant Draximage, Inc. (A Subsidiary of Jubilant Pharma)
11.15 Pharmalogic
11.16 Institute of Isotopes Co., Ltd
11.17 Sinotau Pharmaceuticals Group)
11.18 Isotopia Molecular Imaging Limited
11.19 Shine Medical Technologies
11.20 Global Medical Solutions, Ltd
For more information about this report visit https://www.researchandmarkets.com/r/hrulg
